These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26622090)

  • 1. Atherogenic Dyslipidemia and Residual Vascular Risk in Practice of Family Doctor.
    Alibasic E; Ramic E; Bajraktarevic A; Ljuca F; Batic-Mujanovic O; Zildzic M
    Med Arch; 2015 Oct; 69(5):339-41. PubMed ID: 26622090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?
    Halcox J; Misra A
    Metab Syndr Relat Disord; 2015 Feb; 13(1):1-21. PubMed ID: 25402738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
    Fruchart JC; Sacks FM; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P;
    Diab Vasc Dis Res; 2008 Nov; 5(4):319-35. PubMed ID: 18958843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of atherogenic dyslipidemia in the primary care setting in Spain.
    Díaz Rodríguez Á; Blasco Valle M; Mantilla Morató T; Capón Alvarez J; Rodríguez de Miguel M; Rodríguez-Fortúnez P; Prada-Marcos C; Orera-Peña ML
    Clin Investig Arterioscler; 2019; 31(5):203-209. PubMed ID: 31320121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome update.
    Grundy SM
    Trends Cardiovasc Med; 2016 May; 26(4):364-73. PubMed ID: 26654259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B; Buldak L; Bołdys A
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population.
    Kutkiene S; Petrulioniene Z; Laucevicius A; Matuzeviciene G; Kasiulevicius V; Petrulionyte E; Staigyte J; Saulyte A; Gargalskaite U; Skiauteryte E; Kovaite M; Rinkuniene E
    Lipids Health Dis; 2018 Sep; 17(1):208. PubMed ID: 30185180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.
    Diamantopoulos EJ; Athyros VG; Yfanti GK; Migdalis EN; Elisaf M; Vardas PE; Manolis AS; Karamitsos DT; Ganotakis ES; Hatseras D;
    Angiology; 2005; 56(6):731-41. PubMed ID: 16327950
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.